Protagonist Therapeutics, Inc PTGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
13.41
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $46.0M | -$130.1M | — | $56.1M | $614.7M |
| 2024 | $434.4M | $275.2M | — | $182.8M | $675.3M |
| 2023 | $60.0M | -$79.0M | — | -$70.8M | $336.7M |
| 2022 | $26.6M | -$127.4M | — | -$108.9M | $215.6M |
| 2021 | $27.4M | -$125.6M | — | -$109.0M | $300.0M |
| 2020 | $28.6M | -$66.2M | — | -$73.0M | $279.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Waddill William D. | director | 2026-06-23 | Option exercise | 9,000 | $16.54 |
| Waddill William D. | director | 2026-06-23 | Sell | 9,000 | $117.94 |
| Waddill William D. | director | 2026-06-10 | Option exercise | 3,000 | $11.80 |
| Waddill William D. | director | 2026-06-10 | Sell | 9,000 | $107.68 |
| Waddill William D. | director | 2026-06-10 | Option exercise | 6,000 | $16.54 |
| Waddill William D. | director | 2026-05-29 | Sell | 9,000 | $99.64 |
| Waddill William D. | director | 2026-05-29 | Option exercise | 9,000 | $11.80 |
| PATEL DINESH V PH D | President and CEO | 2026-05-12 | Option exercise | 75,000 | $21.58 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 13.41 (safe)
- Working capital / assets 0.796
- Retained earnings / assets -0.704
- EBIT / assets -0.237
- Equity / liabilities 11.494
Source: SEC EDGAR filings · CIK 0001377121 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.